Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Retained Earnings (2016 - 2025)

Rein Therapeutics (RNTX) has disclosed Retained Earnings for 10 consecutive years, with -$401.3 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 14.19% to -$401.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$401.3 million through Dec 2025, down 14.19% year-over-year, with the annual reading at -$401.3 million for FY2025, 14.19% down from the prior year.
  • Retained Earnings for Q4 2025 was -$401.3 million at Rein Therapeutics, down from -$369.3 million in the prior quarter.
  • The five-year high for Retained Earnings was -$10000.0 in Q1 2023, with the low at -$401.3 million in Q4 2025.
  • Average Retained Earnings over 5 years is -$193.8 million, with a median of -$253.4 million recorded in 2021.
  • Peak annual rise in Retained Earnings hit 99.99% in 2021, while the deepest fall reached 23865600.0% in 2021.
  • Over 5 years, Retained Earnings stood at -$13000.0 in 2021, then tumbled by 2098246.15% to -$272.8 million in 2022, then dropped by 5.77% to -$288.5 million in 2023, then fell by 21.8% to -$351.4 million in 2024, then decreased by 14.19% to -$401.3 million in 2025.
  • According to Business Quant data, Retained Earnings over the past three periods came in at -$401.3 million, -$369.3 million, and -$44000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.